Latest News
News
Psoriasis registry study provides more data on infliximab’s infection risk
Infliximab was associated with a statistically significant increased risk of serious infection, compared with non-biologic systemic treatments.
Conference Coverage
Psoriasis pipeline is full of biologics
CHICAGO – “The IL-23 blockers are ideal for patients who want a few injections.”
News
FDA announces plan for biosimilar innovation and competition
One proposed step is to release a series of videos that explain key concepts about biosimilar and interchangeable products.
News
Extended data support ixekizumab for plaque psoriasis
An open-label, 4-year extension study of ixekizumab yields promising results.
News
Elderly patients with psoriasis can benefit from biologics with low rates of adverse events
Age should not be the deciding factor in which psoriasis patients receive treatment with these powerful therapies, according to Italian...
Conference Coverage
Adalimumab strikes out for aortic inflammation in psoriasis
ORLANDO – Ustekinumab shows promise, but “we are still not certain.”
News
Psoriasis therapy with biologics not linked to increased cancer risk
The international case-control study using registry data looked at risk in real-world clinical practice.
Conference Coverage
CBC values linked to CVD risk in psoriasis
ORLANDO – Red cell distribution width – a measure of the range of red blood cell volumes in a given sample – and mean platelet volume are...
Conference Coverage
Hidradenitis suppurativa packs mighty QOL impact
KAUAI, HAWAII – Quality of life burden is greater with hidradenitis suppurativa than psoriasis.
Conference Coverage
Psoriasis duration reflects cardiovascular event risk
For every year of psoriasis, a patient’s risk of a major cardiovascular event climbs an additional 1%.